Search

Displaying results 6261 - 6270 of 7687 in total
  1. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  2. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR
  3. Drug

    CTX120

    go.drugbank.com/drugs/DB18625
    Investigational

    CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.

  4. Drug

    Isopentane

    go.drugbank.com/drugs/DB16203
    Investigational

    Isopentane is under investigation in clinical trial NCT00752089 (Experimental Dentifrice Remineralization/fluoride Uptake in an in Situ Model).

  5. Drug

    Avoplacel

    go.drugbank.com/drugs/DB18659
    Investigational

    Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.[L48370]

  6. Drug

    IL15-NK Cell

    go.drugbank.com/drugs/DB15725
    Investigational

    Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity.

  7. Drug

    Guanosine

    go.drugbank.com/drugs/DB02857
    Investigational

    Guanosine can be phosphorylated to become GMP (guanosine monophosphate), cGMP (cyclic guanosine monophosphate), GDP (guanosine diphosphate) and GTP (guanosine triphosphate) which are factors in signal

    Synonyms: 9-β-D-ribofuranosyl-guanine, Guanine-9-β-D-ribofuranoside
  8. Drug

    Leuprolide

    go.drugbank.com/drugs/DB00007
    ApprovedInvestigational

    Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three … [L13850] Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months.

  9. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  10. Drug

    Sparfosic acid

    go.drugbank.com/drugs/DB03459
    Experimental

    These are compounds containing an alpha amino acid which bears an acyl group at the terminal nitrogen atom.